Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Attwell

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Current Oncology (Toronto, Ont.)|June 23, 2010
Adjuvant interferon alfa for melanomaKenneth S Wilson, Andrew Attwell
Urologic Oncology|August 30, 2014
Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experienceEmily Baxter, Kristopher Dennis, Christian Kollmannsberger, et al.
The Lancet. Oncology|November 16, 2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trialDaniel J Khalaf, Matti Annala, Sinja Taavitsainen, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Current Oncology (Toronto, Ont.)|June 23, 2010
Adjuvant interferon alfa for melanomaKenneth S Wilson, Andrew Attwell
Urologic Oncology|August 30, 2014
Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experienceEmily Baxter, Kristopher Dennis, Christian Kollmannsberger, et al.
The Lancet. Oncology|November 16, 2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trialDaniel J Khalaf, Matti Annala, Sinja Taavitsainen, et al.
Pageof 1